

IN THE CLAIMS

1-22. (Cancelled)

23: (Currently Amended) A culture medium comprising a chicken serum and a culture support comprising inactivated 3T3 cells of the cell line registered in the ATCC collection under the number CCL92, wherein the 3T3 cells are derived from the 3T3 cells of the cell line registered in the ATCC collection under the number CCL92 by means of a method comprising the steps of inoculation into wells, culture, transfer, culture, detachment by trypsinization, freezing half of each subclone, treatment of the other half with mitomycin C or with gamma rays, incubation of chicken keratinocytes on each treated subclone, culture, fixing and staining with rhodamine B, and selection of the subclone on which there are the largest number of keratinocyte colonies of the largest size.

24: (Previously Presented) The culture medium as claimed in claim 23, wherein the proportion by weight of chicken serum relative to the total weight of the culture medium is between 0.5 and 50%.

25. (Cancelled).

26: (Previously Presented) The culture medium as claimed in claim 23, wherein the 3T3 cells have been inactivated by an antimitotic treatment selected from treatment with mitomycin C or irradiation with gamma rays.

27: (Previously Presented) The culture medium as claimed in claim 23, wherein the culture medium comprises one or more of the following constituents: inorganic salts, vitamins, hormones and growth factors.

28: (Previously Presented) The culture medium as claimed in claim 23, wherein the culture comprises one or more of the following constituents: inorganic salts, amino acids, vitamins, fatty acids, glucose, a buffer, phenol red, EGF (epidermal growth factor), T<sub>3</sub>, hydrocortisone, insulin, cholera toxin, transferrin and adenine.

29: (Previously Presented) An avian keratinocyte culture comprising a culture medium that comprises chicken serum and a culture support comprising inactivated fibroblasts.

30: (Previously Presented) The keratinocyte culture as claimed in claim 29, wherein the culture medium that comprises chicken serum and a culture support comprising inactivated fibroblasts comprises inactivated 3T3 cells of the cell line registered in the ATCC collection under the number CCL92.

31: (Previously Presented) The keratinocyte culture as claimed in claim 30, wherein the keratinocytes are chicken keratinocytes.

32: (Currently Amended) A method of culturing avian ~~epidermal cells or~~ keratinocytes, comprising:

- (i) preparing a suspension of the keratinocytes;
- (ii) inoculating said keratinocytes cells into a culture medium comprising chicken serum and a culture support comprising inactivated fibroblasts; and
- (iii) incubating said keratinocytes cells in the culture medium.

33: (Previously Presented) The method as claimed in claim 32, wherein the culture medium comprises a chicken serum and a culture support comprising inactivated 3T3 cells of the cell line registered in the ATCC collection under the number CCL92.

34: (Currently Amended) The method of culture as claimed in claim 32, wherein at the end of step (iii), the keratinocytes cells derived from the culture are recovered and a further culture cycle is applied to them according to steps (ii) and (iii) ~~of the method as claimed in claim~~

35: (Previously Presented) The method of culture as claimed in claim 34, comprising at most 30 cell culture cycles.

36: (Currently Amended) A method of propagating a virus in vitro, comprising:

- (i) infecting keratinocytes with the strain of the virus;
- (ii) placing the infected keratinocytes in culture according to the method of claim 32; and
- (iii) extracting the virions produced in step (ii).

37: (Previously Presented) The method as claimed in claim 36, comprising a step of lyophilization of the virions.

38: (Currently Amended) The method as claimed in claim 36, wherein the avian keratinocytes are chicken keratinocytesepidermal cells.

39: (Previously Presented) The method as claimed in claim 36, wherein the virus is selected from MDV and FPV.

40: (Currently Amended) A method for the preparation of a medicine for the prevention or treatment of Marek's disease, comprising a method according to claim 36, and introducing the virion obtained into a pharmaceutically acceptable carrier.

41: (Withdrawn) A complete, acellular, live, attenuated enveloped DNA virion from a virus FPV, obtained by a method as claimed in claim 32.

42: (Withdrawn) A live attenuated vaccine, comprising at least one virion as claimed in claim 41 and a vaccine support.

43: (Withdrawn) A complete, acellular, live, attenuated enveloped DNA virion from a virus FPV, obtained by a method as claimed in claim 36.

44: (Withdrawn) A live attenuated vaccine, comprising at least one virion as claimed in claim 43 and a vaccine support.